Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech ...

CEO of Maravai LifeSciences. “We plan to further evolve and enhance Molecular Assemblies’ workflows to push the limits of oligo length and purity, and to lower costs by vertically integrating ...

Maravai LifeSciences (MRVI) announced its acquisition of intellectual property and relevant assets from Molecular Assemblies, or MAI. The ...

SAN DIEGO - Maravai LifeSciences, Inc. (NASDAQ: MRVI), a $796 million market cap company known for supplying life science reagents and services, has announced the acquisition of intellectual property ...

Trey Martin, CEO of Maravai LifeSciences, expressed confidence in the potential advancements the acquisition could bring, stating their intention to evolve Molecular Assemblies' workflows.

Molecular Assemblies proprietary Fully Enzymatic Synthesis TM technology to enhance mRNA and oligonucleotide manufacturing capabilities within the TriLink BioTechnologies business SAN DIEGO--(BUSINESS ...